SMARCB1 involvement in the development of leiomyoma in a patient with schwannomatosis.

Am J Surg Pathol

*Department of Genome Analysis, Academic Medical Center ∥Department of Pathology, VU University Medical Center, Amsterdam §Department of Pathology, Nijmegen Center for Molecular Life Sciences (NCMLS), Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands †Institute for Human Genetics, University Hospital Muenster, Muenster ‡Institute for Neuropathology, Evangelisches Krankenhaus, Bielefeld, Germany.

Published: March 2014

Germline SMARCB1 mutations predispose in schwannomatosis patients to the development of multiple benign schwannomas and, in some cases, meningiomas. Here, we report on a 34-year-old female patient who developed multiple schwannomas at various locations and in addition a leiomyoma of the cervix uteri. She carried a c.362+1G>A mutation that inactivates the donor splice site of exon 3. This mutation caused the schwannomatosis phenotype in this patient and was also demonstrated to be present in her affected mother. The leiomyoma displayed the genetic features that are characteristic for germline SMARCB1 mutation-associated tumors. The mutant allele retained in the tumor, whereas the wild-type allele was lost by loss of heterozygosity. Furthermore, the loss of heterozygosity involved net loss of chromosome 22. An NF2 mutation was not found. However, quantitative polymerase chain reaction suggested that both NF2 copies were lost in the tumor. Immunostaining with a SMARCB1 antibody revealed the mosaic expression pattern that is typical for schwannomatosis-associated tumors. To our knowledge, this is the first reported case of leiomyoma associated with a germline SMARCB1 mutation. As such, it widens the spectrum of benign tumors associated with a germline SMARCB1 mutation.

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000110DOI Listing

Publication Analysis

Top Keywords

germline smarcb1
16
loss heterozygosity
8
associated germline
8
smarcb1 mutation
8
smarcb1
6
mutation
5
smarcb1 involvement
4
involvement development
4
leiomyoma
4
development leiomyoma
4

Similar Publications

Rhabdoid tumours (RT) are an aggressive malignancy affecting <2-year-old infants, characterised by biallelic loss-of-function alterations in SWI/SNF-related BAF chromatin remodelling complex subunit B1 (SMARCB1) in nearly all cases. Germline SMARCB1 alterations are found in ~30% of patients and define the RT Predisposition Syndrome type 1 (RTPS1). Uveal melanoma (UVM), the most common primary intraocular cancer in adults, does not harbour SMARCB1 alterations.

View Article and Find Full Text PDF
Article Synopsis
  • This study examined 16 cases of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), focusing on clinical features, molecular traits, and family genetics over a decade at Fudan University.
  • Patients had a mean diagnosis age of 28.7 years, with unique tumor characteristics; most were unilateral, with significant sizes, and misdiagnosed in many cases, while specific protein expressions were analyzed.
  • Survival rates over time were low, with only 22.6% surviving two years, highlighting the need for accurate diagnosis and better understanding of the disease's genetic components.
View Article and Find Full Text PDF

A novel mutation in SMARCB1 associated with adult Coffin-Siris syndrome and meningioma.

Acta Biochim Biophys Sin (Shanghai)

November 2024

Henan Provincial Key Laboratory of Genetic Diseases and Functional Genomics, Medical Genetics Institute of Henan Province, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou 450000, China.

Article Synopsis
  • The text discusses a gene that encodes a key part of the SWI/SNF chromatin remodeling complex, important for gene expression regulation, linked to Coffin-Siris syndrome type 3 (CSS3).
  • A family with two adult patients having a new missense mutation (c.1091A>C, p.Lys364Thr) was studied, revealing issues with verbal learning and language delays.
  • One patient developed meningioma, and findings suggest the mutation may improperly activate the MAPK signaling pathway, highlighting a connection between genetic mutations, neurodevelopmental disorders, and tumor formation.
View Article and Find Full Text PDF

Approaches for prevention of tumors in patients with rhabdoid tumor predisposition syndrome.

Neurooncol Adv

September 2024

Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Patients with rhabdoid tumor predisposition syndrome (RTPS) harbor germline alterations in the epigenetic regulator genes or . Patients usually present with atypical teratoid/rhabdoid tumor (AT/RT) of the brain or malignant rhabdoid tumor (MRT) arising outside the central nervous system. Intensive treatment can lead to remissions, however tumors frequently recur or synchronous or metachronous tumors appear.

View Article and Find Full Text PDF
Article Synopsis
  • Malignant rhabdoid tumors mainly affect young children and are linked to genetic changes in the SMARCB1 gene; about 30% of patients have one altered SMARCB1 allele, leading to poorer outcomes.
  • A study of 29 patients with sporadic rhabdoid tumors investigated the frequency and impact of constitutional mosaicism (having mutated genes in some but not all cells) using advanced DNA sequencing techniques.
  • The research found constitutional mosaicism in 21% of patients, suggesting it is common in these tumors; however, there were no significant differences in clinical outcomes between patients with and without mosaicism, indicating more research is necessary.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!